Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| SYRE | CLUSTER | bearish | 5/10 | Three insiders at Spyre Therapeutics, including the CEO and CFO, sold shares totaling $920K over a one-week window. Dire | Aug 10, 2026 |
| BHVN | 8-K | neutral | 5/10 | Biohaven reported Q2 2026 financial results with a GAAP net loss of $137.3M ($0.91/share), significantly wider than the | Aug 10, 2026 |
| FF | 8-K | bullish | 7/10 | FutureFuel Corp. reported a transformative Q2 2026, swinging from a net loss of ($14.2M) to net income of $11.4M, driven | Aug 10, 2026 |
| CATX | 8-K | neutral | 5/10 | Perspective Therapeutics reported Q2 2026 results with a net loss of $26.8M ($0.22/share), narrower than the $0.29 loss | Aug 10, 2026 |
| TECH | PREM14A | bullish | 7/10 | Bio-Techne (TECH) filed a preliminary proxy statement (PREM14A) for a special shareholder meeting to vote on its acquisi | Aug 10, 2026 |
| DNTH | 144 | neutral | 2/10 | Simon Read, an officer of Dianthus Therapeutics, filed a Form 144 to sell 5,550 shares of common stock valued at approxi | Aug 10, 2026 |
| ANNX | 8-K | neutral | 4/10 | Annexon announced the resignation of board member Muneer Satter (after 11+ years) and the immediate appointment of Dr. M | Aug 10, 2026 |
| DMAC | 8-K | bullish | 7/10 | DiaMedica reported Q2 2026 EPS of -$0.19, a 5% beat vs. the -$0.20 consensus, but net loss widened to $10.1M from $7.7M | Aug 10, 2026 |
| ONC | 144 | bearish | 6/10 | Chairman and CEO John Oyler filed a Form 144 on August 10, 2026, signaling intent to sell approximately $83.9 million wo | Aug 10, 2026 |
| PTGX | 144 | bearish | 5/10 | CEO Dinesh Patel filed a Form 144 notice of intent to sell 225,000 shares of Protagonist Therapeutics (PTGX) through J.P | Aug 10, 2026 |
| AAWH | DEFA14A | neutral | 4/10 | Ascend Wellness Holdings (AAWH) filed a DEFA14A reminder urging stockholders to vote 'FOR' a reverse stock split (ratio | Aug 10, 2026 |
| CYCN | 425 | neutral | 4/10 | Cyclerion Therapeutics filed a Rule 425 communication on August 10, 2026, consisting of social media posts (X and Linked | Aug 10, 2026 |
| LTGO | CLUSTER | bullish | 6/10 | Two insiders at Latigo Biotherapeutics, a director/10% owner and a 10% owner, purchased a combined 280,000 shares for $5 | Aug 10, 2026 |
| AMGN | CLUSTER | neutral | 2/10 | Two senior Amgen executives (SVP & CCO and SVP, Human Resources) executed open-market sales totaling $1.63M on August 6, | Aug 10, 2026 |
| LEXX | 8-K | bearish | 7/10 | Lexaria Bioscience Corp. (LEXX) received a delisting notification from Nasdaq on August 4, 2026, for failing to regain c | Aug 10, 2026 |
| NATR | INSIDER-BUY | bullish | 5/10 | A 10% owner, Prescott Group Capital Management, purchased approximately 4,500 shares of NATR for ~$75K on August 6, 2026 | Aug 10, 2026 |
| TRDA | CLUSTER | neutral | 2/10 | Two TRDA insiders, Director Kush Parmar and 10% owner 5AM Ventures, collectively sold ~21K shares for $147K in open-mark | Aug 10, 2026 |
| BLSM | CLUSTER | bullish | 7/10 | Multiple insiders at BlossomHill Therapeutics made significant open-market purchases totaling ~$5.18M, led by director/1 | Aug 10, 2026 |
| IFF | CLUSTER | neutral | 2/10 | Two IFF insiders (CFO and Controller) sold a combined $840K in open-market transactions over two days. The total value r | Aug 10, 2026 |
| CRBP | CLUSTER | neutral | 4/10 | CEO Yuval Cohen and CFO Sean Moran sold a combined $292K in open-market transactions on August 7, 2026, representing ~0. | Aug 10, 2026 |
| ELTP | 8-K | neutral | 3/10 | Elite Pharmaceuticals filed an 8-K announcing that its Q1 FY2027 financial results will be released on August 13, 2026, | Aug 10, 2026 |
| ELAN | CLUSTER | neutral | 3/10 | Two Elanco insiders (Director Herendeen and CFO VanHimbergen) made open-market purchases totaling $334K in the week foll | Aug 10, 2026 |
| MRK | CLUSTER | neutral | 2/10 | Four Merck executives sold a combined ~$12M in open-market shares over two days following the Q2 2026 earnings release. | Aug 10, 2026 |
| ATTO | CLUSTER | bullish | 8/10 | Four major 10% owners (Sanofi, Redmile, venBio, Frazier Life Sciences) collectively purchased $25M in open-market shares | Aug 10, 2026 |
| IMNM | CLUSTER | neutral | 3/10 | Two insiders at Immunome (IMNM) sold a total of ~$2.82M in shares over a 7-day window. The CBO sold $2.27M after exercis | Aug 10, 2026 |
| SLN | 424B5 | bearish | 7/10 | Silence Therapeutics is conducting a $150M underwritten public offering of ADSs, announced concurrently with positive Ph | Aug 10, 2026 |
| ENTA | 8-K | bullish | 7/10 | Enanta reported a narrower-than-expected net loss of $0.45 per share for fiscal Q2 2026, beating the consensus estimate | Aug 10, 2026 |
| VERA | 8-K | neutral | 5/10 | Vera Therapeutics reported Q2 2026 earnings: net loss of $109.5M ($1.52/share) vs. $76.5M ($1.20/share) in Q2 2025, with | Aug 10, 2026 |
| OLMA | 8-K | neutral | 5/10 | Olema Pharmaceuticals reported a Q2 2026 net loss of $63.2M, wider than the $43.8M loss in Q2 2025, driven by increased | Aug 10, 2026 |
| HROW | PRESS-RELEASE | bearish | 8/10 | No summary provided | Aug 10, 2026 |